The Need for Novel Asexual Blood-Stage Malaria Vaccine Candidates for Plasmodium falciparum.

ABSTRACT: Extensive control efforts have significantly reduced malaria cases and deaths over the past two decades, but in recent years, coupled with the COVID-19 pandemic, success has stalled. The WHO has urged the implementation of a number of interventions, including vaccines. The modestly effective RTS,S/AS01 pre-erythrocytic vaccine has been recommended by the WHO for use in sub-Saharan Africa against Plasmodium falciparum in children residing in moderate to high malaria transmission regions. A second pre-erythrocytic vaccine, R21/Matrix-M, was also recommended by the WHO on 3 October 2023. However, the paucity and limitations of pre-erythrocytic vaccines highlight the need for asexual blood-stage malaria vaccines that prevent disease caused by blood-stage parasites. Few asexual blood-sta

SUBMITTER: Takashima E 

PROVIDER: S-EPMC10813614 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature